Table 2.
Changes in protein expression of various biomarkers and their mutational status and progression free survival
| Mutational status of tumor | PFS (Days) | PI3K (% change) | pPI3K (% change) | IGF1R (% change) | pMEK (% change) | cMET (% change) | pERK (% change) | pAKT (% change) | |
|---|---|---|---|---|---|---|---|---|---|
| BRAF | 385 | -99.5 | -97.1 | -93.6 | - | -72.3 | - | -83.9 | |
| Wt | 275 | -46.3 | -75.3 | -61 | -92.9 | -75.8 | -96.8 | -90.4 | |
| KRAS + PIK3CA | 274 | -39.7 | 54.9 | 0 | 0 | 378.7 | 1570 | 2653.9 | |
| Wt | 252 | -97.7 | 0 | -59.3 | 0 | -86 | -93.3 | -61.5 | |
| Wt | 484 | -86 | -86.8 | -95.3 | 0 | -97.1 | -87.5 | 210 | |
| Wt | 236 | -63.2 | -96.7 | -99.4 | -94.2 | -73.1 | -98.1 | -98.7 | |
| Wt | 109 | -99.8 | 0 | 59.1 | 0 | 1261 | 30.6 | -64.3 | |
| BRAF | 106 | 483.3 | 97.3 | 1630 | 0 | 473.3 | 540 | 975 | |
| NRAS | 106 | -92.7 | -96.8 | -97.2 | -92.5 | -93.5 | -99 | -64.3 | |
| KRAS + PIK3CA | 105 | -99.9 | 0 | 0 | 0 | 1864.5 | 0 | -81.8 | |
| KRAS | 48 | 36020 | -38.3 | 38.6 | 730 | 561.7 | 1490 | 2653.9 | |
| KRAS | 47 | 180 | 770 | 7.6 | -37.1 | 324.8 | 1.3 | 571 | |
| BRAF + KRAS | 49 | 159.7 | -96.5 | 12.7 | -94.2 | 20 | -81.6 | -97.5 | |
| PIK3CA + NRAS | 49 | -85.7 | -99.6 | -99.9 | -97.6 | -86.4 | -96.2 | -81.3 | |
| *Test of null hypothesis P value | 0.01 | 0.50 | 0.12 | 0.57 | 0.07 | 0.53 | 0.70 |
Wt – Wild-type.
Negative % change reflects downregulation; positive % change reflects upregulation.
*Mann Whitney U test (2-tailed) of PFS between patient populations with upregulated or downregulated protein expression.